Aegerion Pharmaceuticals Appoints Marc Beer as CEO

Aegerion Pharmaceuticals Appoints Marc Beer as CEO


BRIDGEWATER, N.J.--(BUSINESS WIRE)--Sep 13, 2010 - Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today announced that Marc Beer has joined the company as both CEO and a member of the Board of Directors.

Marc brings over 20 years of experience in biotechnology, pharmaceuticals and diagnostics to Aegerion. In 2000 he became the founding CEO of ViaCell, a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells, and over a period of 7 years, led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 on NASDAQ under the ticker VIAC, and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).

Prior to founding ViaCell, Marc held various positions within Genzyme (NASDAQ: GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT).

He also previously served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Body and was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts.

Marc currently holds the following board seats: Chairman, TxCell, Nice, France; Chairman, Good Start Genetics, Cambridge, MA; Board Member, Seaside Therapeutics, Cambridge, MA. Mr. Beer holds a B.S. from Miami University.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's primary focus is on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase III testing.

 

 

Contact: Aegerion Pharmaceuticals, Inc.
Christine Pellizzari, 908-707-2100
Executive Vice President, General Counsel and Secretary
or
Media:
Sard Verbinnen & Co.
Jim Barron/Lesley Bogdanow
212-687-8080

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.